About OncoMyx Therapeutics

Website
Website
Employees
Employees
1-10 employees View all
Industry
Industry
Pharmaceuticals
Location
Location
850 N 5th Street, Phoenix, AZ 85004, US
Description
Information
OncoMyx Therapeutics targets hematologic and solid tumors with unique oncolytic virus called myxoma (MYXV) and a novel patented systemic delivery approach. The myxoma program is the result of two decades of oncolytic virus research in the laboratory of Professor Grant McFadden. Myxoma is a pox virus that is highly immunostimulatory, and is non-pathogenic in any organism outside of rabbits. The virus has a unique ability to be carried systemically by human leukocytes where it can then infect tumor cells. Programs are in development for both hematology (myeloma and AML) as well as solid tumors. Professor McFadden sequenced the myxoma virus genome in 1999, and since then has produced dozens of genetically engineered constructs, demonstrating its ability as an oncolytic agent across many tumors in preclinical cell and animal models.

OncoMyx Therapeutics Alternatives

Industry
Pharmaceuticals
Industry
pharmaceuticals
Industry
pharmaceuticals
Industry
pharmaceuticals

Frequently Asked Questions about OncoMyx Therapeutics

What is OncoMyx Therapeutics email format?

The widely used OncoMyx Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.


What is OncoMyx Therapeutics customer service number?

To contact OncoMyx Therapeutics customer service number in your country click here to find.


Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.

Discover the source of our data

Learn more